Hepatocellular Carcinoma, Liver Transplantation
Conditions
Brief summary
Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death worldwide. Liver transplantation (LT) is the best curative treatment of HCC meeting Milan/UCSF criteria. Milan (solitary tumour \<5cm, or up to 3 tumours, each \<3cm) and University of California San Francisco (UCSF) criteria (solitary tumour ≤6.5cm, up to 3 tumours with none \>4.5cm, and total tumour diameter ≤8cm) provide the benchmark requirements for LT, at which a 5-year survival of \>70% and recurrence rate ranging from 5-15% can be achieved. Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for advanced HCC. Neo-adjuvant TAI for the HCC patients with beyond criteria serving as a down-staging method for the advanced HCC to meet Milan/UCSF criteria，and qualify for LT. This study is to compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan/UCSF Criteria HCC who underwent LT.
Interventions
OTHERTransarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
TAI
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. older than 18 years old and younger than 75 years listed for liver transplant; 2. ECOG PS≤1; 3. Child-Pugh Stage A or B 4. Proven hepatocellular carcinoma according patological examination or EASL/AASLD diagnostic criteria; 5. Not previous treated for tumor; 6. The tumor was diagnosed beyond Milan criteria or University of San Francisco criteria for LT 7. No distant metastasis; 8. The lab test could meet: Neutrophil count≥2.0×109/L; Hemoglobin≥100g/L; Platelet count≥75×109/L; Serum albumin≥35g/L; Total bilirubin\<2-times upper limit of normal; ALT\<3-times upper limit of normal; AST\<3-times upper limit of normal; Serum creatine\<1.5-times upper limit of normal; PT≤upper limit of normal plus 4 seconds; INR≤2.2; 9. Sign up consent.
Exclusion criteria
1. Cannot tolerate TAI or LT; 2. Distant metastasis exits; 3. Known history of other malignancy; 4. Be allergic to related drugs; 5. Be treated before (interferon included); 6. Known history of HIV infection; 7. Known history of drug or alcohol abuse; 8. Have GI hemorrhage or cardiac/brain vascular events within 30 days; 9. Pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | From date of randomization until the date of death from any cause, assessed up to 60 months | From date of randomization until the date of death from any cause, assessed up to 60 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| RFS | From date of randomization until the date of recurrence, assessed up to 60 months | recurrence-free survival |
| recurrence rate | 1 year, 2 year, 3 year, 5 year after surgery | recurrence rate |
| PFS | From date of randomization until the date of progression, assessed up to 60 months | progression free survival |
Countries
China
Contacts
Primary ContactWenjie Zhang, PhD
Outcome results
None listed